Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Completed 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Neoplasms 2Liver Neoplasms 1Diarrhea 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 3155Cisplatin 3151Carboplatin 2929Paclitaxel 2671Radiotherapy 2643Gemcitabine 2544pembrolizumab 2324Docetaxel 2154Bevacizumab 2126Fluorouracil 1819Capecitabine 1780Oxaliplatin 1709Dexamethasone 1589Nivolumab 1516Doxorubicin 1477Rituximab 1453Etoposide 1341Magnetic Resonance Spectroscopy 1261Irinotecan 1232Leucovorin 1212Cytarabine 1123Pemetrexed 1060Drug Therapy 1060fludarabine 1044Vincristine 956Specimen Handling 928Prednisone 924Cetuximab 919Lenalidomide 916Trastuzumab 897

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × shosaiko-to × Clear all
NCT06055179 2025-07-01

XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)

Guangzhou University of Traditional Chinese Medicine

Phase NA Recruiting
98 enrolled
Tumor-Agnostic

Neoplasms

NCT04926545 2024-07-30

XCHT for Irinotecan-Induced Gut Toxicities (Run-in Study)

Guangzhou University of Traditional Chinese Medicine

Phase NA Completed
24 enrolled

Diarrhea, Neoplasms

NCT00040898 2013-01-18

Sho-Saiko-To Following Removal of Liver Cancer By Embolization in Treating Patients With Liver Cancer That Cannot Be Surgically Removed

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡